Reengineering an antiarrhythmic drug using patient hiPSC-cardiomyocytes to improve therapeutic potential and reduce toxicity

Modelling cardiac disorders with human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics. However, disease-relevant physiological assays can be complex, and the use of hiPSC-cardiomyocyte models of congenital disease phen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Stem Cell
Main Authors: McKeithan, Wesley L., Feyen, Dries A. M., Bruyneel, Arne A. N., Okolotowicz, Karl J., Ryan, Daniel A., Sampson, Kevin J., Potet, Franck, Savchenko, Alex, Gómez-Galeno, Jorge, Vu, Michelle, Serrano, Ricardo, George, Alfred L., Kass, Robert S., Cashman, John R., Mercola, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655512/
https://ncbi.nlm.nih.gov/pubmed/32931730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.stem.2020.08.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados